Boehringer Ingelheim and Simcere Collaborate on Novel Treatment for Inflammatory Bowel Disease Boehringer Ingelheim and Simcere announce a partnership to develop SIM0709, a dual-target antibody, to tackle inflammatory bowel disease (IBD) effectively.

Boehringer Ingelheim and Simcere Collaborate on Novel Treatment for Inflammatory Bowel Disease #China #Shanghai #Boehringer_Ingelheim #Simcere #SIM0709